动物造模,生酮饮食 z-bo 2020-09-08 474

　　A recent mouse study published online in the journal Nature showed that a ketogenic diet consisting of high fat, medium protein and low carbohydrates can be combined with drug therapy to improve the therapeutic effect of anti-cancer PI3K inhibitors.

　　Research shows that a combination of diet and targeted therapy can be used to improve drug response. However, the feasibility of translating these results into clinical applications needs further consideration. Researchers have developed several PI3K mutation inhibitors, but it is well known that PI3K mutations can cause cancer. However, because PI3K can regulate glucose metabolism, the use of PI3K inhibitors can cause hyperglycemia and increase insulin levels.

　　Under normal circumstances, this effect is short-lived, but in patients with insulin resistance, this effect still exists. In this case, insulin activates the PI3K signaling pathway in tumors, promotes cancer development, and interrupts PI3K inhibitor therapy. The researchers pointed out that during the treatment process, glucose-insulin feedback appeared in several mouse models, activated the tumor PI3K pathway, and may counteract the anti-tumor effect of the inhibitor. Researchers have found that certain diets and medications can prevent this insulin feedback and improve the effectiveness of inhibitors. In particular, after treatment with PI3K inhibitors, insulin levels in mice on a ketogenic diet decreased. This is because the ketogenic diet consumes a large amount of glycogen stored in the liver and inhibits the release of glucose. The results showed that some mouse models of ketogenic diet had smaller tumors.

　　Researchers have noticed that in different mouse tumor models, the effect of the ketone diet alone is significantly different.